A packed MS market is about to get busier as J&J's ponesimod enters the fray
When J&J dropped $30 billion into an Actelion buyout back in 2017, it hoped the biotech’s pipeline would add something fresh to the massive drugmaker’s slow-to-grow portfolio. One of those mid-stage pickups, MS candidate ponesimod, is now ready for showtime in a busy and growing MS market.
The FDA on Friday approved J&J’s S1P1 receptor modulator ponesimod to treat relapsing multiple sclerosis, the drugmaker said.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
